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LETTER TO THE EDITOR
Sir,
I have read the excellent paper by Shifflet 
and Wu.1
Watanabe et al reported that several meta-
bolic disturbances, such as obesity, insulin resis-
tance, and hepatic steatosis, are significant risk
factors for decreased sustained virologic response
to interferon and ribavirin combination antiviral
therapy in chronic hepatitis C patients.2
It should be noted, for completeness, the influ-
ence of non-alcoholic fatty liver disease (NAFLD) on
post liver transplantation (LT) antiviral treatment.
It is well known that the natural history of re-
current hepatitis C is accelerated after LT. Hepatitis
C driven fibrosis response in the allograft leads
to the development of graft cirrhosis in approxi-
mately 25% of recipients after a follow-up of
5–10 years. More than 10% of patients who un-
dergo transplantation for hepatitis C cirrhosis
eventually require retransplantation for hepatitis
C related graft failure.3
In relation to organ shortage, Llado et al af-
firmed that retransplantation is not an option
for recurrent hepatitis C cirrhosis after LT.4 For
this reason, it is mandatory to protect in the best
way the graft by treating with antiviral therapy
for recurrent hepatitis C.5
In a substantial proportion of infected recipi-
ents, liver injury remains mild despite high viral
burden.
Several factors have been clearly shown to be
associated with fibrosis progression rate. Metabolic
conditions and steatosis are emerging as inde-
pendent cofactors of fibrogenesis.
Machicao et al suggested that allograft steato-
sis is a common occurrence after orthotopic liver
transplantation (metabolic alterations, immuno-
suppression) and is independent of concomitant
HCV infection.6
Till now, in our experience, there is evidence
for the importance of parameters such as body
mass index (BMI, kg/m2), cholesterol (mg/dL),
triglycerides (TG, ng/mL) and hepatic percentage
of steatosis in response to therapy with pegylated
interferon (PEG-IFN) alfa-2b and ribavirin in 
patients with recurrent hepatitis C after LT.7
Response to therapy was evaluated in relation
to virologic response (HCV-RNA assay was per-
formed at 1, 3, 6, 12 and 18 months): sustained
virologic response (SVR) was defined as the ab-
sence of serum HCV-RNA (virologic remission)
and serum alanine aminotransferase (ALT) activity
within the reference range for at least 6 months
after; sustained biochemical response (SBR) was
defined as a decrease in serum ALT activity to with-
in the reference range but with reappearance or
persistently detectable serum HCV-RNA; non-
response (NR) was defined as persistence/relapse
at the end of therapy of HCV-RNA and no decrease
in ALT activity or relapse at the end of therapy.
Ten patients (31.2%) stopped therapy for side
effects, SVR was observed in six cases (6/22,
27.2%), SBR in seven cases (7/22, 31.8%) and NR
in nine cases (9/22, 40.9%).
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The observed distributions of BMI, cholesterol,
TG and percentage of steatosis were confirmed to
be normally distributed by the one-sample
Kolmogorov-Smirnov Goodness of Fit test proce-
dure. Comparison of BMI, cholesterol, TG and per-
centage of steatosis among NR, SVR and SBR groups
were analyzed by ANOVA with a post hoc Bonfer-
roni test and correlation between variables was
tested by Pearson’s test. The univariate analysis was
performed to estimate the probability of response
on the basis of the above mentioned variables.
BMI, TG, and percentage of steatosis in the NR
group (26.8 ± 3.3, 245.3 ± 84.4 and 26.8 ± 23.6,
respectively) were higher than the values observed
in the SVR group (20.4±2.6, p<0.001; 108.3±48.4,
p = 0.002; 5.75 ± 2.2, p = 0.027, respectively) and
the SBR group (21.5 ± 1.6, p = 0.003; 132.4 ± 51.2,
p = 0.008; 6.2 ± 2.4, p = 0.033, respectively). The
differences between the SVR and SBR groups were
not significant for the above mentioned variables.
As for cholesterol, no significant differences were
registered in the NR (197.6 ± 47.3), SVR (149.3 ±
37) and SBR (153.4 ± 41.5) groups.
Pearson’s correlation test (correlation coeffi-
cient > 0.7, p < 0.001 for every correlation) showed
a strong correlation between BMI, cholesterol,
TG and percentage of steatosis.
For patients with BMI < 25 and TG < 160, the
chance of SVR was 48 times higher than that of
NR. The chances of SVR and SBR for patients with
percentage of steatosis < 15 were 12 times more
than that with higher percentage of steatosis 
values.
The observed diminished response has been
hypothesized to be due to decreased IFN bioavail-
ability in overweight patients, presence of hepatic
steatosis, which itself is a predictor of poor re-
sponse to antiviral treatment.8 Moreover, increased
expression of suppressor of cytokine that inhibit
IFN signaling may be one mechanism by which
overweight reduces the IFN response.8
Some authors have postulated that the possi-
ble altered immune function in obesity may be
mediated by leptin resistance. Leptin is an im-
portant modulator of the Th-1 response.9 It is
possible that patients with steatosis resulting
from insulin resistance and not virally mediated
may be unable to upregulate adequately the Th-1
response via IFN because of underlying signifi-
cant leptin resistance. This could lead to altered
viral clearance and a decrease in SVR.9
It is known that retransplantation is not an
option for recurrent hepatitis C cirrhosis after LT.
Therefore, our experience tells us the importance
of a better histologic and internistic evaluation
in order to reach the highest number of SVR in
patients with recurrent hepatitis C.
We can conclude how the amount of steatosis
can be noted specifically in biopsy examination
reports of patients with relapsed chronic hepatitis
C and how the management of dismetabolism,
diet and exercise therapy can improve BMI, liver
histology and, therefore, the response to antiviral
therapy.
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